Acadia Pharmaceuticals Inc.
ACADAcadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. It is known for its flagship product, Nuplazid (pimavanserin), approved for the treatment of Parkinson's disease psychosis. The company's research and development efforts aim to address unmet medical needs in areas such as schizophrenia, dementia-related psychosis, and other neuropsychiatric conditions.
Company News
Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.
Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.
The Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.
The global neuroregeneration therapy market is expected to grow significantly, driven by advancements in regenerative medicine and the rising prevalence of neurological disorders. Key players are investing heavily in R&D, leading to innovative therapies and clinical trials that are accelerating market expansion.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price...
